Tag Archives: Leqembi: Japan panel recommends approval of Alzheimer medicine

A Japanese health ministry panel on Monday recommended approval of the Alzheimer’s disease treatment Leqembi, following standard approval for the drug granted by U.S. regulators last month. The expert panel’s decision sets the stage for official approval of the drug, co-developed by Japan’s Eisai and U.S.-based Biogen. An Eisai executive said this month the company expects to begin marketing Leqembi …

Read More »